Trial Profile
A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary) ; Cytarabine; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AROG Pharmaceuticals
- 08 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Nov 2017 New trial record